late cgrp parti differenti drive use initi overweight
initi coverag alder overweight rate pt believ
alder under-valued despit late-stag de-risk differenti asset
address larg under-serv migrain popul alder eptinezumab
quarterli iv administ anti-cgrp antibodi prevent frequent episod
chronic migrain fem/cm competitor antibodi teva self
administ subq inject think subset patient warrant/pref
quarterli in-offic infus self-inject underappreci epti faster
onset subq believ financi incent in-offic administr
fee doc also drive use find aldr share attract current
level especi given epti uniqu product featur iv quarterli rapid onset
appar posit launch aimovig bla submiss near
eptinezumab differenti product cusp launch multi-billion
dollar market launch subq cgrp antibodi aimovig fem/cm
prevent late may encourag posit launch commentari
think aimovig report earli success signifi need new migrain prevent
therapi believ migrain prevent market could grow
assum conserv estim candid
treat cgrp antibodi think alder gener meaning sale
iv antibodi target incapacit patient identifi
high-touch procedur specialist specialti sale forc rep
though epti last four cgrp antibodi launch bla submiss
launch think suffici distinguish rapid onset
durabl efficaci iv mode administr captur market
view oral cgrp develop migrain prevent
direct competitor antibodi address differ popul patient
less debilit migrain
valuat pt deriv blend dcf valu weight
ev/revenu multipl sale valu weight estim net epti
price year plu annual price increas complianc rate
note addit upsid potenti ex-u sale current reflect model
alder end cash includ net proce
convert debt offer feb sale prefer stock
jan current cash expect support oper epti bla
submiss addit fund like need commerci launch
alder may unsuccess develop and/ commerci eptinezumab
migrain prevent therapi may fail ind enabl futur clinic studi
alder clinic stage bio-pharmaceut compani focus develop
antibodi treatment migrain
blend dcf weight ev/
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
initi coverag
page
invest summari
think alder iv cgrp monoclon antibodi prevent frequent episod fem chronic migrain cm
suffici differenti three competitor subq inject antibodi drive peak sale
price target aldr dcf indic share valu revenu multipl valuat base
eptinezumab sale yield valu
eptinezumab migrain prevent
epti last four cgrp antibodi launch commerci opportun iv infus conveni
subq inject often come question due epti uniqu product featur believ best suit option
debilit migrain patient furthermor estim address market larg penetr even small
share market drive meaning sale alder
think cgrp antibodi migrain prevent market could grow
page
summari background
page
initi coverag alder biopharmaceut ticker aldr overweight rate pt
alder eptinezumab iv administ anti-cgrp antibodi prevent frequent episod
chronic migrain fem/ cm competitor antibodi amgen/novarti teva administ
home monthli subq inject believ major patient favor home self-administr
think still meaning subset patient warrant prefer quarterli iv infus accord
kol weve previous interact patient requir frequent check-up in-offic
quarterli infus would ideal mani doc exampl would prefer administ treatment patient
complianc issu opinion abil doc bill in-offic iv administr may also incentiv
use iv epti subq cgrp final epti appear faster onset subq competitor
demonstr substanti migrain reduct within dose due high symptomat burden
migrain patient think epti rapid onset particularli import differenti featur
migrain popul need new treatment option especi prevent therapi expect high
adopt rate cgrp antibodi given size migrain market candid
prevent therapi captur even small share meaning
alder think eptinezumab
distinguish enough other penetr least market compani plan target
high-touch procedur specialist person us-bas specialti sale forc forecast
us sale eptinezumab think vast major revenu driven debilit cm
encount sever headwind last year aldr share gain momentum
settlement prior ip litig initi strength aimovig launch bla submiss near
new senior manag place ceo robert azelbi hire june juno
serv evp chief commerci offic still think plenti room addit upsid
find stock attract current level
page
alder pipelin overview catalyst calendar
prevent frequent episod
prevent chronic migrain cm
prevent migrain
out-licens vitaeri
may
expect upcom catalyst mileston
page
aldr share current trade around reach new high
short interest current float
factset price data
page
eptinezumab may fail achiev regulatori approv fda
may fail ind enabl futur clinic studi
alder late entrant migrain prevent market expect face competit
compani commerci experi larger infrastructur
competitor cover chri raymond teva cover david amsellem
biohaven cover tyler van buren allergan cover david amsellem gener
alder state need rais addit capit commerci eptinezumab
 specialti sale forc
page
page
factset price close
page
view discount rate appropri compani
multipl asset late stage clinic develop evalu
discount rang calcul free-cash-flow valuat
recent acquir compani colucid make
page
y/i growth ratecash ratenet fulli dilut free cash flowebiatplu stock-bas compensationplu depreci amortizationless capit expendituresless chang work capitalrevenueebitoper margintax rateless taxesequ valuepric per sharebcdtv perpetu growth rate ofenterpris valueef valuat summari
page
eptinezumab migrain prevent
page
overview eptinezumab
alder lead asset eptinezumab monoclon antibodi belong new class
cgrp initi migrain transmiss caus vasodil neurogen
inflamm character leakag blood vessel degranul mast cell
block cgrp either bind receptor ligand interrupt cgrp abil
may protect sensit nervou system
attack
epti evalu numer clinic trial includ two pivot trial
frequent episod migrain fem chronic migrain cm
epti demonstr clinic statist signific improv primari reduct
monthli migrain day vs placebo secondari respond rate
respond rate etc endpoint promis phase trial
view think littl regulatori risk epti base safeti
efficaci profil data gener competitor anti-cgrp antibodi believ
eventu fda approv foregon conclus investor bear case alder
appear driven amount competit cgrp antibodi epti
last four cgrp antibodi launch commerci opportun
iv infus conveni subq inject often come question
believ epti adequ distinguish competitor address
market quit larg small share need drive meaning
sale alder
page
dynam migrain prophylaxi market
candid
prophylaxi
adher low
seek
due high
burden
diseas
page
although eptinezumab expect last four anti-cgrp antibodi reach market think suffici differenti
one administ quarterli iv infus though often perceiv disadvantag believ benefit
stand alon in-offic quarterli administ drug includ
abil close monitor safety/ efficacy/ complianc prefer sever debilit migrain patient
benefit physician in-offic administr fee
better suit patient uncomfort self-inject
given size address market think captur subset patient still gener eptinezumab revenu
view oral cgrp develop direct competit threat antibodi believ may role oral
cgrp prophylaxi less sever episod migrain patient still cautiou long-term dose capabl oral
due potenti toxic think vast major migraineur requir prophylaxi better suit treatment antibodi
note cover chri raymond teva cover david amsellem cover tyler van buren cover
page
compar efficaci cgrp antibodi chronic
acut med use chang days/ month pbo adj
opinion efficaci gener compar across class
page
eptinezumab rapid onset set apart competitor
benefit observ within administr
migrain reduct baselin
observ day post infus iv eptinezumab maintain full
page
epti deep magnitud effect differenti
follow singl quarterli iv infus epti patient cm trial
fem trial migrain free month percentag patient
respons rate increas subsequ quarterli dose iv epti
page
page
launch end
may
drug price
use net
price estim
although still
earli
launch think
initi uptak
indic
written
valid
need new
page
migrain popul
elig prophylaxi treat
cgrp antibodi estim market
reach sale
believ alder penetr modest
market iv eptinezumab
even small subset translat
annual sale
assum net price per year across class annual price increas
page
cgrp antibodiesmigrain market modelu migrain prophylaxi cgrp prevent migrain treatment subq cgrp market patient aldr market pt patient cgrp migrain prophylaxi market eptinezumab revenu model
cm fem pt
treat neurologist
neurologist
address market
launch
ex-u opportun
reflect partner
yet secur
net price
launch
approxim net price
page
popul increas aldr eptinezumab revenu modelu cm popul popul chronic migrain number patient cm treat treat infus pt treat neurologist w/ infus eptinezumab patient treat per cm sale mm us fem em candid treat fem pt treat infus pt treat neurologist w/ infus patient treat per treatment treatments/ fem sale mm total eptinezumab revenues-
collabor licens revenu
net incom loss common stockhold
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
